RxDoctor Payments Data

Abu Salahuddin, MD

Internal Medicine · Fayetteville, NCNPI 1376596965

Payments from drug & device makers

$5,757in general payments, 2019–2025

Across 374 payments — averaging $15.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$748
  • GSK$587
  • Boehringer Ingelheim$562
  • Novo Nordisk$508
  • AstraZeneca$444
  • Bayer$344
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$5,757100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,757 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$167,651
Medicare patients
257
Services billed
2,426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$142,360
JardianceEmpagliflozin117$141,811
TrulicityDulaglutide66$116,592
EliquisApixaban100$97,063
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$67,306
FarxigaDapagliflozin Propanediol54$62,961
MounjaroTirzepatide47$52,984
JanuviaSitagliptin Phosphate37$46,581
XareltoRivaroxaban35$31,987
Tresiba Flextouch U-200Insulin Degludec25$30,258
RybelsusSemaglutide17$27,577
ProliaDenosumab13$22,940
KerendiaFinerenone11$15,723
AbrysvoRsv Vacc, Pref A And Pref B/Pf47$15,029
VascepaIcosapent Ethyl18$13,287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$508$169,937111 claims
Lilly USA, LLCTrulicity, Mounjaro$748$169,576113 claims
Boehringer IngelheimJardiance$562$141,811117 claims
PfizerEliquis, Abrysvo$231$112,091147 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta$587$83,913118 claims
AstraZenecaFarxiga$444$62,96154 claims
MerckJanuvia$101$46,58137 claims
Johnson & JohnsonXarelto$233$31,98735 claims
AmgenProlia$233$22,94013 claims
BayerKerendia$344$15,72311 claims
AbbVieLinzess$130$10,51712 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$107$9,92712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →